Will Garvin, Shareholder in the firm's FDA & Biotechnology practice, is quoted about a recent Medicare decision and its potential impact in the FDA's work toward regulating laboratory-developed tests as medical devices in Bloomberg BNA's article "Will Medicare Genetic Test Coverage Get Labs to Seek FDA Signoff?"